UBS Group
OYST

UBS Group’s Oyster Point Pharma, Inc. Common Stock OYST Stock Holding History

UBS Group’s Portfolio OYST Stock Details OYST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,787
Closed -$176K – 11533
2022
Q4 		$176K Buy
15,787
+13,123
+493% +$127K ﹤0.01% 5562
2022
Q3 		$15K Buy
2,664
+417
+19% +$2.61K ﹤0.01% 7877
2022
Q2 		$10K Buy
2,247
+1,249
+125% +$7.1K ﹤0.01% 8077
2022
Q1 		$12K Sell
998
-2,600
-72% -$31K ﹤0.01% 8254
2021
Q4 		$66K Buy
+3,598
New +$45.6K ﹤0.01% 6679
2021
Q3 		– Sell
-829
Closed -$14K – 10439
2021
Q2 		$14K Sell
829
-816
-50% -$15.5K ﹤0.01% 7739
2021
Q1 		$30K Sell
1,645
-19
-1% -$398 ﹤0.01% 7028
2020
Q4 		$31K Buy
1,664
+750
+82% +$16.2K ﹤0.01% 6618
2020
Q3 		$20K Sell
914
-2,993
-77% -$70K ﹤0.01% 6323
2020
Q2 		$113K Buy
3,907
+633
+19% +$19.1K ﹤0.01% 5213
2020
Q1 		$115K Sell
3,274
-3,681
-53% -$119K ﹤0.01% 5173
2019
Q4 		$170K Buy
+6,955
New +$122K ﹤0.01% 5701

Other funds holding OYST

HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS Group's OYST Position: Q1 2023 in Review

UBS Group sold out of Oyster Point Pharma, Inc. Common Stock (OYST) in Q1 2023, closing a stake of 15,787 shares — an estimated $176K sold.

UBS Group first reported a position in OYST in Q4 2019 and held it in 12 quarters. The position peaked at $176K in Q4 2022. 1 fund tracked by Wall St. Rank holds OYST as of Q1 2023.

  • UBS Group reported no remaining Oyster Point Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • UBS Group sold 15,787 Oyster Point Pharma, Inc. Common Stock shares in Q1 2023, an estimated $176K.
  • UBS Group first reported a position in Oyster Point Pharma, Inc. Common Stock in Q4 2019 and held it in 12 quarters.
  • UBS Group's Oyster Point Pharma, Inc. Common Stock position peaked at $176K in Q4 2022.
  • 1 fund tracked by Wall St. Rank held Oyster Point Pharma, Inc. Common Stock as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.